Clarus Therapeutics Holdings

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Los Angeles, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Clarus Therapeutics (CRXT) fell by 31.16% today. This is why.

Clarus Therapeutics (CRXT) Stock: Why It Fell 31.16%

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Agile Therapeutics

Baudax Bio

Nine Energy Service

Quanergy Systems

Revelation Biosciences

Alaunos Therapeutics

Trevi Therapeutics Inc

Mammoth Energy Services

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

The stock price of Clarus Therapeutics (CRXT) fell by 36.94% in the most recent trading session. This is why.

Clarus Therapeutics (CRXT) Stock: Why It Fell 36.94%

Source: arfa adam / Shutterstock.com Clarus Therapeutics (NASDAQ: CRXT ) stock is falling hard on Monday as investors prepare for the stock to be delisted later this week. Shares of CRXT stock will no longer trade on the Nasdaq Exchange on Aug. 31, which is this Wednesday.

Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting

Palisade Bio

Timber Pharmaceuticals

T2 Biosystems

Penny stocks under $1 to watch this week. The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week

Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million

Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

Geovax Labs

Verb Technology Company Inc

Check these tips out for your penny stocks buy list right now The post Top Tricks for Trading Penny Stocks Right Now, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Tricks for Trading Penny Stocks Right Now, 3 Tips

JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

Sorrento Therapeutics Inc

Yatsen Holding

Are these penny stocks worth buying right now? The post Hot Penny Stocks to Buy This Week?

Hot Penny Stocks to Buy This Week? 3 to Watch Right Now

Blue Hat Interactive Entertainment Technology

Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in July?

Hot Penny Stocks to Buy in July? Check These 3 Out

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT ) Q1 2022 Earnings Conference Call May 16, 2022 5:15 PM ET Company Participants Bob Dudley - Founder, President and CEO Ric Peterson - CFO Frank Jaeger - Chief Commercial Officer Conference Call Participants Operator Thank you for joining in the Clarus First Quarter 2022 Financial and Operating Results Conference Call. Today's call is being recorded and webcast live on the company's website at www.clarustherapeutics.com in the Investor Relations section, and it will be available for replay for 10 days following this live call.

Clarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcript

First quarter 2022 net revenue increased 72% year-over-year to $4.0 million

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes.

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

DBV Technologies SA Sponsored ADR

Transocean

Are these penny stocks on your watchlist right now? The post Hot Penny Stocks You Need to Know About This Month  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks You Need to Know About This Month

IT Tech Packaging Inc

Sesen Bio Inc.

Statera Biopharma Inc

Hot penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Buy For Under $1 This Week

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the closing of its previously announced underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock (or pre-funded warrant) was sold together with one Class A warrant at a combined purchase price of $1.10 per unit (or $1.10 (less) $0.001 (the exercise price of the pre-funded warrants) for units comprising pre-funded warrants and accompanying Class A warrants). The Class A warrants are immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Class A warrants could only be purchased together in the offering, but were issued separately and were immediately separable upon issuance. The pre-funded warrants and the Class A warrants are not listed on any exchange. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding the proceeds from the exercise of any Class A warrants, were approximately $30.0 million. In addition, Clarus has granted the underwriters a 45-day option to purchase up to an additional 4,090,608 shares of common stock and/or Class A warrants to purchase up to 4,090,608 shares of common stock to cover over-allotments at the offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 4,090,608 Class A warrants.

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

Checkpoint Therapeutics

XpresSpa Group

Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) shares are trading lower by 52.82% at $0.85 after the company announced an upsized $30 million underwritten public offering at $1.10 per share.  The offering is expected to close on April 27, 2022, subject to customary closing conditions.

Why Clarus Therapeutics Shares Are Getting Hammered

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of its underwritten public offering of (i) units consisting of 26,680,720 shares of its common stock and accompanying Class A warrants to purchase up to 26,680,720 shares of its common stock and (ii) units consisting of pre-funded warrants to purchase up to 590,000 shares of common stock and accompanying Class A warrants to purchase up to 590,000 shares of common stock. Each share of common stock (or pre-funded warrant) is being sold together with one Class A warrant at a combined purchase price of $1.10 per unit (or $1.10 (less) $0.001 (the exercise price of the pre-funded warrants) for units comprising pre-funded warrants and accompanying Class A warrants). Clarus also granted the underwriter an option to purchase up to an additional 4,090,608 shares of common stock and/or Class A warrants to purchase up to 4,090,608 shares of common stock. The Class A warrants will be immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Class A warrants can only be purchased together in the offering, but will be issued separately and will be immediately separable upon issuance. The pre-funded warrants and the Class A warrants will not be listed on any exchange. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding the proceeds from the exercise of any Class A warrants and the exercise of the underwriter's overallotment option, are expected to be approximately $30.0 million. The offering is expected to close on April 27, 2022, subject to customary closing conditions.

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

News for Clarus Therapeutics Holdings Stock (CRXT)